Optimisation of circulating biomarkers of cell death for routine clinical use

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 990-995

  Greystoke, A ^a,b   Cummings, J ^a   Ward, T ^a   Simpson, K ^a   Renehan, A ^c   Butt, F ^a   Moore, D ^a   Gietema, J ^d   Blackhall, F ^b,c   Ranson, M ^b,c   Hughes, A ^c,e   Dive, C ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Cell death biomarkers; Clinical utility; M30; M65; Small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CYTOKERATIN 18; ETOPOSIDE; ICE; PLATINUM COMPLEX;

ARTICLE; BLOOD SAMPLING; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG SMALL CELL CANCER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROTEIN SECRETION; RELIABILITY; ROOM TEMPERATURE; STORAGE TEMPERATURE; TIME;

EID: 43049111423     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn014     Document Type: Article

References (27)

1. S. Holdenrieder P. Stieber H. Bodenmuller Nucleosomes in serum of patients with benign and malignant diseases Int J Cancer 95 2001 114 120
2. G.A. Roth C. Krenn M. Brunner Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients Shock 22 2004 218 220
3. A. Gonzalez-Quintela J. Garcia J. Campos Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19 Alcohol 38 2006 45 49
4. C. Adlbrecht K. Hoetzenecker M. Posch Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction Eur J Clin Invest 37 2007 372 380
5. J. Cummings M. Ranson E. Lacasse Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP Br J Cancer 95 2006 42 48
6. J. Cummings T.H. Ward E. LaCasse Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP Br J Cancer 92 2005 532 538
7. S. Holdenrieder P. Stieber J. VON Pawel Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments Ann N Y Acad Sci 1075 2006 244 257
8. M.F. Pichon M. Labroquere K. Rezai Variations of soluble fas and cytokeratin 18-asp 396 neo-epitope in different cancers during chemotherapy Anticancer Res 26 2006 2387 2392
9. K. Barczyk M. Kreuter J. Pryjma Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy Int J Cancer 116 2005 167 173
10. K. Neuber B. Eidam Expression of fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival Onkologie 29 2006 361 365
11. R. Moll W.W. Franke D.L. Schiller The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells Cell 31 1982 11 24
12. L. Galluzzi M.C. Maiuri I. Vitale Cell death modalities: classification and pathophysiological implications Cell Death Differ 14 2007 1237 1243
13. G. Kramer S. Schwarz M. Hagg Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles Br J Cancer 94 2006 1592 1598
14. T. Ueno M. Toi K. Biven Measurement of an apoptotic product in the sera of breast cancer patients Eur J Cancer 39 2003 769 774
15. E. Ulukaya A. Yilmaztepe S. Akgoz The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival Lung Cancer 56 2007 399 404
16. Peviva M30-Apotosense ELISA Instructions for Use 2005 Peviva Sweden
17. N.J. Webb M.J. Bottomley C.J. Watson P.E. Brenchley Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease Clin Sci (Lond) 94 4 1998 395 404
18. A.V. Hoffbrand D. Catovsky E.G.D. Tuddenham Postgraduate haemeatology 2005 Blackwell Malden, Mass 1080
19. DRG Instruments CYFRA 21-1 ELISA Instructions for Use (ed 2005-03-01), DRG Instruments 2005
20. M.J. Evans J.H. Livesey M.J. Ellis T.G. Yandle Effect of anticoagulants and storage temperature on stability of plasma and serum hormones Clin Biochem 34 2 2001 107 112
21. P. Seed Comparing several methods of measuring the same quality Stata Tech Bull 10 2001 73 82
22. J. Cummings M. Ranson F. Butt Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma Cancer Chemother Pharmacol 60 2007 921 924
23. M.H. Oloffson T. Ueno Y. Pan Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy Clin Cancer Res 13 2007 In press
24. W.E. Hoffmann N. Everds M. Pignatello P.F. Solter Automated and semiautomated analysis of rat alkaline phosphatase isoenzymes Toxicol Pathol 22 6 1994 633 638
25. R. Einarsson J.D. Lei A. Ullrich A. Van Dalen Performance characteristics of IMMULITE TPS: A comparison with TPS IRMA Anticancer Res 19 4A 1999 2743 2747
26. M. Sarwar K. Tomiyoshi T. Inoue K. Fukazawa K. Endo CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay Ann Nucl Med 8 4 1994 301 306
27. Peviva: M30-Apoptosense ELISA Instructions for Use (ed 2007-01-29), Peviva 2007